Selisistat

Drug Profile

Selisistat

Alternative Names: EX-527; SEN 0014196; SEN196

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elixir Pharmaceuticals
  • Developer Siena Biotech
  • Class Amides; Antineoplastics; Carbazoles; Neuroprotectants; Small molecules
  • Mechanism of Action SIRT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 02 Oct 2017 AOP Orphan Pharmaceuticals AG acquires selisistat
  • 20 Feb 2015 Pharmacokinetics and adverse events data from a phase I trial in Healthy volunteers released by Siena Biotech
  • 20 Feb 2015 Pharmacokinetics, pharmacodynamic and adverse events data from a phase I/II trial in Huntington's disease released by Siena Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top